Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers

Cancer Research

Volumn 57, Issue 6, 1997, Pages 1054-1057

  Joseph, Ingrid B J K ^a   Isaacs, John T ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; ROQUINIMEX; VASCULOTROPIN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CASTRATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION;

ADENOCARCINOMA; ANDROGENS; ANIMALS; CELL HYPOXIA; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYQUINOLINES; LYMPHOKINES; MALE; MICE; MICE, SCID; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; NEOVASCULARIZATION, PATHOLOGIC; ORCHIECTOMY; PROSTATIC NEOPLASMS; SPECIFIC PATHOGEN-FREE ORGANISMS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0030891344     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Crawford, E. D., Eisenberger, M. A., McLeod, D. C., Spaulding, J., Benson, R., Door, F. A., Blumenstein, B. A., Davis, M. A., and Goodman, P. J. A control randomized trial of Leuprolide with and without flutamide in prostate cancer. N. Engl. J. Med., 321: 419-424, 1989.
2. Yagoda, A., and Petrylak, D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer Suppl., 71: 1098-1109, 1993.
3. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Natl. Med., 1: 27-31, 1995.
4. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
5. Folkman J. Tumor angiogenesis. In: J. Mendelssohn, P. Howley, L. A. Liotta, and M. Israel (eds.), The Molecular Basis of Cancer, pp. 206-232. Philadelphia: W. B. Saunders, 1995.
6. Klagsbrun M., and D'Amore, P. A., Regulation of angiogenesis. Annu. Rev. Physiol., 53: 217-239, 1991.
7. Ichikawa, T., Lamb, J. C., Christensson, P. J., Hartley-Asp, B., and Isaacs, J. T. The antitumor effect of the quinolene-3-carboxamide Linomide on Dunning R-3327 rat prostatic cancers. Cancer Res., 52: 3022-3028, 1992.
8. Vukanovic, J., and Isaacs, J. T. Human prostate cancer cells are sensitive to programmed (apoptotic) death induced by an antiangiogenic agent, Linomide. Cancer Res., 55: 3517-3520, 1995.
9. Vukanovic, J., Passaniti, A., Hirata, T., Traystman, R. J., Hartley-Asp, B., and Isaacs, J. T. Antiangiogenic effects of the quinoline-3-carboxamide Linomide. Cancer Res., 53: 1833-1837, 1993.
10. Vukanovic, J., and Isaacs, J. T. Linomide inhibits angiogenesis, growth metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res., 55: 1499-1504, 1995.
11. Joseph, I. B. J. K., and Isaacs, J. T. The antiangiogenic agent, Linomide inhibits TNF-α secretion via inhibition of its synthesis. Prostate, 29: 183-190, 1996.
12. Joseph, I. B. J. K., Vukanovic, J., and Isaacs, J. T. Antiangiogenic treatment with Linomide as chemoprevention for prostate, seminal vesicle and breast carcinogenesis in rodents. Cancer Res., 56: 3404-3408, 1996.
13. Kyprianou N., and Isaacs, J. T. Activation of programmed cell death in rat ventral prostate following castration. Endocrinology, 122: 552-562, 1988.
14. Kyprianou N., English, H. F., and Isaacs, J. T. Programmed cell death during regression of the PC-82 human prostate cancer following androgen ablation. Cancer Res., 50: 3748-3753, 1990.
15. Hartley-Asp, B., Vukanovic, J., Joseph, I. B. J. K., Strandgarden, K., Polacek, J., and Isaacs, J. T. Anti-angiogenic treatment with Linomide as adjuvant to surgical castration in experimental prostate cancer. J. Urol., in press, 1997.
16. Cullinan-Bove, K., and Koos, R. D. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology, 133: 829-837, 1993.
17. Hyder, S. M., Stancel, G. M., Chiappetta, C., Murthy, L., Boettger-Tony, H., and Makela, S. Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res., 56: 3954-3960, 1996.
18. Banerjee, S. K., Sarkar, D. K., De, A., and Campbell, D. R. Effect of estrogen on expression of vascular endothelial growth factor (VEGF) during estrogen-induced pituitary tumorigenesis in rat. Proc. Am. Assoc. Cancer Res., 37: 222, 1996.
19. Berse, B., Brown., L. F., Van De Water, L., Dvorak, H. F., and Senger, D. R. Vascular permeability factor (vascular endothelial growth factor gene) is expressed differentially in normal tissues, macrophages, and tumors. Mol. Biol. Cell, 3: 211-220, 1992.
20. Brown, L. F., Berse, B., Jackman, R. W., Tongazzi, K., Guidi, A. J., Dvorak, H. F., Senger, D. R., Conolly, J. L., and Schnitt, S. J. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol., 26: 86-91, 1995.
21. Isaacs, J. T. Development and characteristics of the available animal model systems for the study of prostatic cancer. In: D. S. Coffey, W. A. Gardner, Jr., N. Bruchovsky, and M. Resnick (eds.), Current Concepts and Approaches to the Study of Prostate Cancer. Progress in Clinical and Biological Research, pp. 513-576. New York: Alan R. Liss, 1987.
22. Vukanovic, J., Hartley-Asp, B., and Isaacs, J. T. Inhibition of tumor angiogenesis and at the therapeutic ability of Linomide against rat prostatic cancers. Prostate, 26: 235-246, 1995.
23. Koos, R. D., and Olson, C. E. Hypoxia stimulates expression of the vascular endothelial growth factor (VEGF), a putative angiogenic factor, by granulosa cells of the ovarian follicle, a site of angiogenesis. J. Cell Biol., 115: 421a, 1991.
24. Stavri, G. T., Hong, Y., Zachary, I. C., Breier, G., Baskerville, P. A., Yla-Herttuala, S., Risau, W., Martin, J. F., and Erusalimsky, J. D. Hypoxia and platelet-derived growth factor-BB synergistically up-regulate expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett., 358: 311-315, 1995.
25. Minchenko, A., Bauer, T., Salceda, S., and Caro, J. Hypoxic stimulation of vascular endothelial growth factor in vitro and in vivo. Lab. Invest., 71: 374-379, 1994.
26. Shweiki, D., kin, A., Soffer, D., and Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-induced angiogenesis. Nature (Lond.), 359: 843-845, 1992.
27. Plate, K. H., Breier, G., Millauer, B., Ullrich, A., and Risau, W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res., 53: 5822-5827, 1993.
28. Levy, A. P., Levy, N. S., Loscalzo, J., Calderone, A., Takahashi, Yeo, K-T., Koren, G., Colucci, W. S., and Goldberg, M. Regulation of vascular endothelial growth factor in cardiac myocytes. Ore. Res., 76: 758-766, 1995.